Japan’s OTC Rhinitis Market: Consumer Behavior and Market Structure Drive Strong Demand

In Japan, it is common for people to visit a clinic on the same day they notice physical discomfort, receive a consultation, and obtain a prescription without prior appointment. No referral is required, and patients typically bear only 30% of the medical cost thanks to nationalized health insurance. This healthcare environment underpins the relatively low psychological and financial barriers to seeking medical care in Japan.

However, seasonal allergic rhinitis represents a notable exception to this general pattern. As rhinitis is perceived as a familiar long term condition that recurs annually, carries low urgency, and shows limited perceived differences in effectiveness between prescription and over-the-counter (OTC) treatments, self-management through the purchase of medication at drugstores is widely regarded as a rational and sufficient option.

In addition, allergy symptoms such as coughing, sneezing, and a runny nose are often associated with concerns about being mistaken for having a common cold or an infectious disease in public settings. This sensitivity reflects a broader cultural tendency to be considerate of social context and those around oneself. Furthermore, discomfort and reduced concentration caused by rhinitis symptoms are widely recognized as directly affecting academic and work performance, reinforcing a strong inclination to manage symptoms promptly rather than leave them untreated.

As a result, OTC rhinitis medications in Japan have become firmly established as a form of everyday infrastructure, routinely kept on hand to maintain daily functioning.

Underlying this behavior is the widespread prevalence of hay fever and allergic rhinitis across Japanese society. It is estimated that approximately 49.2% of the population has experienced some form of symptoms of hay fever or allergic rhinitis, leading the condition to be commonly described as a “national ailment” in Japan [1].

Demand for rhinitis medication rises sharply during the spring pollen season in particular. For many people, rhinitis is not perceived as a temporary or isolated discomfort, but rather as a chronic, recurring condition that must be managed on an annual basis.

As the United States represents one of the largest allergic rhinitis pharmaceutical markets globally, it serves as an appropriate benchmark for assessing the characteristics of the Japanese market. Accordingly, a comparative analysis between Japan and the U.S. is presented in Table 1 to highlight differences in market structure and demand intensity.

As the United States represents one of the largest allergic rhinitis pharmaceutical markets globally, it serves as an appropriate benchmark for assessing the characteristics of the Japanese market. Accordingly, a comparative analysis between Japan and the U.S. is presented in Table 1 to highlight differences in market structure and demand intensity.

Comparison of the Allergic Rhinitis Drug Market (U.S. vs. Japan)

While the U.S. market is larger in absolute terms, Japan’s market size reaches a comparable level despite having only around one-third of the U.S. population. On a per-capita basis, Japan significantly exceeds the U.S., indicating a high-demand-density market. This suggests that demand for OTC rhinitis medication in Japan is structurally strong and driven by factors beyond population size alone.

When developing products or expanding within Japan’s OTC rhinitis market, it is essential to understand the following three consumer perspectives.

1. Perceived Effectiveness

The highest priority for Japanese consumers is whether the product “actually works.”

Speed of onset and the degree to which symptoms are alleviated are the most frequently cited factors in consumer reviews. Rather than focusing on detailed knowledge of active ingredients, consumers tend to value whether it is intuitively clear—at a glance on the package—that the product will relieve their current symptoms.

In practice, drugstore shelves in Japan are organized by symptom type rather than by ingredient, reinforcing symptom-based decision-making and encouraging consumers to select products based on which symptoms they wish to address.

2. Minimal Side Effects (Particularly Drowsiness)

As these medications are typically used while commuting, working, or studying, minimizing side effects—particularly drowsiness and reduced concentration—is a critical decision criterion for consumers. Products perceived as “safe to use during work” or “appropriate before driving” are therefore strong determinants of consumer choice.

3. Ease of Integration into Daily Routines

As rhinitis medications are often taken daily over an extended period, consumers place strong importance on ease of use and minimal disruption to everyday life. Products that offer sustained effectiveness with once- or twice-daily dosing, as well as formulations that can be easily incorporated into daily routines, tend to be evaluated more favorably.

Below is a ranking of the top 10 rhinitis medications by purchase volume between January and March 2025.[3]

Japan’s OTC rhinitis market clearly demonstrates that high demand density, culturally embedded self-care behaviors, and performance-oriented symptom management create a uniquely structured opportunity landscape. For pharmaceutical and healthcare companies seeking to enter or expand within this market, success depends not only on product efficacy but on a deep understanding of consumer psychology, retail dynamics, and seasonally driven demand cycles. At CarterJMRN, we combine on-the-ground expertise in Japanese healthcare behavior with rigorous qualitative and quantitative methodologies to uncover the true drivers of purchase, switching, and brand loyalty. Whether you are evaluating product positioning, refining communication strategy, or exploring unmet needs within Japan’s highly competitive OTC and prescription markets, our team delivers actionable insights rooted in real-world patient and pharmacist perspectives. We welcome the opportunity to partner with you on your next planned medical market research in Japan and help you navigate this high-potential market with confidence and clarity.

[1] Tamaoki, J., Sakashita, M., Harunari, T., & Okubo, K. (2019). Epidemiological Survey of

Allergic Rhinitis in Japan 2019. Journal of Otolaryngology of Japan, 123(6), 485–494. Accessed at (2025-12-13) from https://www.jstage.jst.go.jp/article/jibiinkoka/123/6/123_485/_article/Accessed at (2025-12-13)

[2] DelveInsight.

Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast – 2034.

DelveInsight Business Research LLP.

Accessed at (2025-12-19) from

https://www.delveinsight.com/report-store/allergic-rhinitis-market

[3] 流通ニュース. (2025, April 22).

TRUE DATAによるID-POSデータ分析：鼻炎用薬 2025年1〜3月 購入個数ランキング.

Accessed at (2025-12-19) from

https://www.ryutsuu.biz/pos/r20250422001.html

© 2026 CarterJMRN. All rights reserved.

This report was prepared by CarterJMRN based on secondary research and market analysis.